bhlha9 Antibody

What is BHLHA9 and what is its biological significance?

BHLHA9 (Basic Helix-Loop-Helix Family Member A9) is a class II basic helix-loop-helix transcription factor encoded by a single exon gene located on chromosome 17p13.3 . This protein functions as a transcription factor involved in the regulation of embryonic development, particularly limb morphogenesis. BHLHA9 is specifically expressed in the distal mesenchyme of E10.5-E11.5 mouse embryo limb buds during the patterning of digital rays of the autopods . Its significance lies in its role as an essential component of the regulatory network governing limb development, as evidenced by studies showing that homozygous bhlha9 knockout mice display various degrees of simple incomplete webbing of forelimb digits 2-3 .

What are the structural characteristics of BHLHA9?

BHLHA9 belongs to the basic helix-loop-helix (bHLH) family of transcription factors, which share two functional domains:

• A basic domain that binds to regulatory E-box DNA sequences

• A helix-loop-helix domain that facilitates homo- or heterodimerization with other HLH protein monomers

The DNA-binding region is highly conserved and contains critical amino acids necessary for proper function. Mutations affecting this region (particularly positions 71, 73, and 75) have been associated with mesoaxial synostotic syndactyly, underscoring the importance of this domain in proper limb development .

What types of BHLHA9 antibodies are currently available for research applications?

Based on current antibody databases, there are multiple BHLHA9 antibodies available for research use:

Most commercially available BHLHA9 antibodies are polyclonal antibodies derived from rabbit hosts, with Western blotting (WB) being the most commonly validated application .

What are the essential validation steps for BHLHA9 antibodies prior to experimental use?

Before using BHLHA9 antibodies in critical experiments, researchers should conduct the following validation steps:

• Positive and negative controls: Test the antibody against:

  • Recombinant BHLHA9 protein or cells overexpressing BHLHA9

  • Tissues known to express BHLHA9 (e.g., developing limb buds)

  • BHLHA9 knockout tissues or cells as negative controls

• Specificity assessment: Verify that the antibody recognizes a protein of the expected molecular weight (~20-25 kDa for BHLHA9)

• Cross-reactivity testing: Ensure the antibody does not detect other closely related bHLH family proteins

• Immunostaining pattern assessment: For immunohistochemistry applications, confirm that staining patterns match the expected nuclear or cytoplasmic localization patterns described in the literature

• Blocking peptide competition: Use the immunizing peptide to confirm signal specificity

How can BHLHA9 antibodies be optimized for Western blot analysis?

For optimal Western blot detection of BHLHA9:

• Sample preparation:

  • For tissues: Use RIPA buffer with protease inhibitors

  • For nuclear proteins: Consider nuclear extraction protocols to enrich for transcription factors

• SDS-PAGE conditions:

  • Use 12-15% gels to resolve BHLHA9 protein (expected size: 20-25 kDa)

  • Include positive controls such as recombinant BHLHA9 protein

• Transfer and blocking:

  • PVDF membranes are recommended for transcription factor detection

  • Block with 5% non-fat dry milk or BSA in TBST

• Antibody dilution and incubation:

  • Primary antibody: Start with 1:500 to 1:1000 dilution and optimize

  • Incubate overnight at 4°C to enhance sensitivity

• Signal detection:

  • Enhanced chemiluminescence (ECL) is suitable for detecting BHLHA9

  • Consider using HRP-conjugated secondary antibodies at 1:5000 to 1:10000 dilution

These recommendations are based on general practices for bHLH transcription factor detection and should be optimized for each specific antibody .

What are the key considerations for immunohistochemical detection of BHLHA9?

When performing immunohistochemistry with BHLHA9 antibodies:

• Tissue preparation and fixation:

  • 4% paraformaldehyde fixation is recommended for limb tissue

  • For embryonic tissue, shorter fixation times (4-8 hours) may better preserve epitopes

• Antigen retrieval:

  • Heat-induced epitope retrieval in citrate buffer (pH 6.0) is often effective

  • Optimize retrieval conditions based on fixation method and tissue type

• Antibody dilution:

  • Start with manufacturer's recommended dilution (typically 1:100 to 1:500)

  • Include positive control tissues (developing limb buds) and negative controls

• Detection system:

  • Polymer-based detection systems often provide better signal-to-noise ratio

  • DAB (3,3'-diaminobenzidine) substrate is commonly used for visualization

• Counterstaining and analysis:

  • Light hematoxylin counterstain to visualize tissue architecture

  • Analyze nuclear localization as expected for transcription factors

When interpreting results, BHLHA9 expression should be observed primarily in the distal mesenchyme of developing limb buds, as reported in the literature .

How can BHLHA9 antibodies be used to study protein-protein interactions?

BHLHA9 functions through dimerization with other bHLH proteins. The following techniques can be employed to study these interactions:

• Co-immunoprecipitation (Co-IP):

  • Use BHLHA9 antibodies to pull down protein complexes from cell or tissue lysates

  • Western blot for potential partners such as TCF3, TCF4, and TCF12, which have been identified as potential dimerization partners

  • Use stringent washing conditions to minimize non-specific binding

• Proximity Ligation Assay (PLA):

  • Provides in situ visualization of protein interactions

  • Utilize BHLHA9 antibody in combination with antibodies against suspected binding partners

  • Especially useful for studying interactions in tissue sections

• Chromatin Immunoprecipitation (ChIP):

  • Use BHLHA9 antibodies to identify DNA binding sites and potential target genes

  • Focus on E-box elements, which are known binding sites for bHLH proteins

  • ChIP-seq can provide genome-wide binding profiles

When designing experiments, consider that BHLHA9 has been shown to dimerize with class I bHLH proteins (E proteins) including TCF3, TCF4, and TCF12, and this dimerization affects the transcription activation potential of these proteins .

What strategies can be employed to study BHLHA9 mutations using antibodies?

For investigating BHLHA9 mutations similar to those found in mesoaxial synostotic syndactyly (MSSD):

• Mutation-specific antibodies:

  • Consider generating antibodies that specifically recognize mutant forms (N71D, R73P, R75L)

  • Use these for differential detection of wild-type versus mutant proteins

• Functional assay approaches:

  • Use existing antibodies to compare expression, localization, and stability of wild-type versus mutant BHLHA9

  • Transfect cells with wild-type or mutant BHLHA9 constructs and perform immunofluorescence to assess subcellular localization differences

• Protein-protein interaction analysis:

  • Compare the ability of wild-type versus mutant BHLHA9 to bind partner proteins like TCF3, TCF4, and TCF12

  • Use co-IP with BHLHA9 antibodies followed by Western blotting for partner proteins

• Transcriptional activity assessment:

  • Use luciferase reporter assays with E-box elements to compare wild-type and mutant BHLHA9 activity

  • Immunoblot for BHLHA9 expression to normalize for protein levels

Research has shown that BHLHA9 harboring mutations in the DNA-binding domain (N71D, R73P, R75L) loses the ability to modulate transcription activation by class I bHLH proteins, suggesting these mutations disrupt critical protein functions .

What are common challenges when detecting BHLHA9 and how can they be addressed?

Common issues when working with BHLHA9 antibodies include:

• Low signal intensity:

  • Increase antibody concentration or incubation time

  • Try more sensitive detection methods (e.g., amplified detection systems)

  • Optimize antigen retrieval methods for IHC

  • Use fresh tissue samples or properly stored proteins to prevent degradation

• High background or non-specific binding:

  • Increase blocking time or concentration

  • Use more stringent washing conditions

  • Try different blocking agents (BSA, normal serum, commercial blockers)

  • Reduce secondary antibody concentration

  • Pre-absorb antibody with non-specific proteins

• Inconsistent results between experiments:

  • Maintain consistent experimental conditions

  • Use the same lot of antibody when possible

  • Include positive controls in each experiment

  • Standardize protein extraction and handling methods

• Nuclear protein detection difficulties:

  • Use specialized nuclear extraction protocols

  • Add phosphatase inhibitors to preserve phosphorylation status

  • Consider crosslinking before extraction

• Antibody specificity concerns:

  • Validate with genetic models (knockout/knockdown)

  • Perform blocking peptide competition assays

  • Try alternative antibodies targeting different epitopes

How can immunofluorescence protocols be optimized for BHLHA9 detection in cell culture models?

For effective immunofluorescence detection of BHLHA9 in cell culture:

• Cell fixation:

  • 4% paraformaldehyde (10-15 minutes) preserves protein structure

  • Methanol/acetone fixation (as used in published protocols) can improve nuclear protein detection

• Permeabilization:

  • Use 0.1-0.5% Triton X-100 to ensure antibody access to nuclear proteins

  • Optimize permeabilization time (5-15 minutes) to balance antigen preservation and accessibility

• Blocking:

  • 5-10% normal serum matching the secondary antibody host

  • Include 0.1-0.3% Triton X-100 in blocking buffer to reduce non-specific binding

• Antibody dilution and incubation:

  • Primary antibody: Start with 1:100 dilution and optimize

  • Extend incubation time (overnight at 4°C) for better signal-to-noise ratio

  • Secondary antibody: 1:200-1:500 dilution, 1-2 hours at room temperature

• Counterstaining and mounting:

  • DAPI for nuclear visualization

  • Use antifade mounting medium to prevent photobleaching during imaging

Research protocols have successfully used anti-MYC tag antibodies (1:100 dilution) to detect MYC-tagged BHLHA9 in transfected cells, with Alexa Fluor 594-conjugated secondary antibodies (1:200 dilution) .

How do BHLHA9 antibodies contribute to understanding developmental limb disorders?

BHLHA9 antibodies enable researchers to investigate several key aspects of limb development disorders:

• Expression pattern analysis:

  • Immunohistochemistry using BHLHA9 antibodies can map expression patterns during critical stages of limb development

  • Comparison between normal and pathological samples can reveal altered expression

• Functional pathway investigation:

  • Co-IP with BHLHA9 antibodies helps identify interaction partners in the limb development regulatory network

  • ChIP techniques can identify downstream target genes affected by BHLHA9 mutations

• Mutation consequence assessment:

  • Compare subcellular localization of wild-type versus mutant BHLHA9 in patient-derived cells

  • Assess protein stability and turnover differences between normal and mutant proteins

• Therapeutic development support:

  • Screen for compounds that may rescue mutant BHLHA9 function

  • Monitor changes in BHLHA9 expression or localization in response to therapeutic interventions

Research has established that mutations affecting the DNA-binding domain of BHLHA9 are associated with mesoaxial synostotic syndactyly, characterized by fusion of the central digits . Antibody-based techniques have been instrumental in demonstrating that these mutations disrupt the normal function of BHLHA9 in regulating gene expression during limb development.

What are the considerations for using BHLHA9 antibodies in comparative evolutionary studies?

When using BHLHA9 antibodies for evolutionary studies across species:

• Epitope conservation assessment:

  • Verify the conservation of the antibody's target epitope across species

  • Sequence alignment of the immunizing peptide region is essential

  • Antibodies targeting highly conserved regions (like the basic domain) may have better cross-reactivity

• Cross-reactivity validation:

  • Test antibodies on known positive controls from each species

  • Validate with recombinant proteins or overexpression systems when possible

  • Consider Western blot validation before proceeding to more complex applications

• Species-appropriate protocol modifications:

  • Adjust fixation and antigen retrieval methods for different tissue types

  • Optimize blocking conditions to reduce species-specific background

  • Modify antibody concentrations and incubation times for each species

• Antibody selection strategies:

  • Choose antibodies raised against conserved domains when studying multiple species

  • Consider species-specific antibodies for detailed expression studies

  • For zebrafish studies, specific antibodies like anti-BHLHA9 (AA 51-82) are available

Current commercially available antibodies include those reactive with human, mouse, and zebrafish BHLHA9, allowing for comparative studies across these model organisms .